

ABOUT CERIBELL

Ceribell, Inc. (www.ceribell.com), is headquartered in Mountain View, CA. Ceribell is focused on making EEG widely available, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures.

Quotes about Ceribell Rapid Response EEG:

- “We are excited to see the growing body of evidence supporting the accuracy and utility the Ceribell Rapid Response EEG system for use in critical care situations where time to diagnosis is essential for making treatment decisions and improving patient outcomes.” Dr. Josef Parvizi, MD, PhD, Co-founder of Ceribell.
- "The Ceribell Rapid Response EEG has a dramatic impact for managing critically ill patients. It provides patients with more precise and accurate care, physicians with a reliable diagnostic tool, and hospitals with clear cost saving opportunities. We are excited to be able to bring this revolutionary technology to physicians across the United States." Jane Chao, PhD, Co-founder and CEO of Ceribell.
- "We have designed the Ceribell EEG System to meet the unmet needs of greater access, efficiency, and cost-effectiveness. This will be particularly beneficial for centers that do not have access to 24/7 EEG." Jane Chao, PhD, Co-founder and CEO of Ceribell.
- "The Ceribell EEG System has the potential to significantly improve the care that we provide to patients that we suspect of having a seizure. The reduced time to EEG and tools to improve our diagnosis will have a meaningful impact for both patients and care providers," said Kyle Hobbs, M.D.
- "We are extremely pleased to have such a strong and diverse syndicate with leaders from pharma, medical device, and best-in-class healthcare investors." Jane Chao, PhD, Co-founder and CEO of Ceribell.
- "Ceribell is transforming how we monitor and diagnose seizures in ICU and ED patients that are at highest risk for poor outcomes. Early and accurate treatment of seizure patients is critical for patients' outcomes, and Ceribell provides the tools to enable early and accurate diagnosis. We believe that Ceribell's groundbreaking innovations will not only save more lives, but also significantly improve the quality of life for patients." Yongzhi Jiang, Partner and Chief Investment Officer at Optimas.
- "Ceribell's unique approach combining user-centric design, AI data analytics, and digital health has the potential to revolutionize how clinicians monitor for seizures and minimize the time from seizure onset to treatment. This platform can not only have a significant positive impact on the health and treatment of patients in the United States, but also more broadly across the world where EEG and trained neurologists are not available," Heath Lukatch, Partner at TPG.

- "We started our mission because we saw how seizure patients in the ICU and ED in even the best US hospitals suffered from delayed treatment due to lack of EEG. Some suffered major neurological deficits while others simply didn't make it. We are excited to see visionary pioneer health care practitioners already adopting our technology and transforming their EEG capability." Jane Chao, PhD, Co-founder and CEO of Ceribell.
- "We saw how seizure patients in the ICU and ED in even the best U.S. hospitals suffered from delayed treatment due to lack of EEG. Some suffered major neurological deficits while others simply didn't make it—we wanted to do our part and help improve patient care." Jane Chao, PhD, Co-founder and CEO of Ceribell.
- "When it comes to EEG, there are significant unmet needs for greater access, efficiency, and cost-effectiveness. Ceribell Rapid Response EEG with Clarity will empower hospitals to have the very best in 24/7 acute care EEG capability, at a fraction of the cost of conventional systems. For the first time, it is possible for physicians to detect non-convulsive status epilepticus within minutes instead of waiting hours or days, allowing them to provide the best care available so they can minimize secondary brain injury." Jane Chao, PhD, Co-founder and CEO of Ceribell.
- "Ceribell's FDA-cleared, portable Rapid Response EEG medical device is a significant improvement from conventional EEGs by enabling doctors to diagnose seizures in minutes, dramatically reducing the timeframe to effectively treat patients and prevent permanent damage." Gerald A. Michaud, President of Horizon
- "Ceribell's advanced technology and medical devices that rapidly monitor brain activity are filling a vital need for doctors and hospitals, providing quick and accurate information that can critically shrink the time needed to diagnose and treat patients from hours to minutes." Jane Chao, PhD, Co-founder and CEO of Ceribell